Definium Therapeutics, Inc. (DFTX) FY2025 10-K Annual Report
Definium Therapeutics, Inc. (DFTX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Definium Therapeutics, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: late-stage clinical biopharma developing psychedelics-based treatments for brain health disorders
- • New emphasis on Phase 3 trials for DT120 ODT targeting GAD and MDD; initiated DT402 Phase 2a trial for autism spectrum disorder in late 2025
- • Strategic shift: rebranded from MindMed to Definium Therapeutics in January 2026, began trading as “DFTX” on Nasdaq
- • Quantitative highlight: DT120 Phase 2b GAD trial showed 7.6-point HAM-A improvement vs placebo (p<0.0004) with 65% response rate sustained to 12 weeks
- • Noteworthy: FDA granted Breakthrough Therapy designation for DT120 in GAD and UK’s MHRA issued Innovation Passport designation in 2024
Management Discussion & Analysis
- • No revenue or profitability data disclosed in the provided MD&A excerpt
- • No segment performance or financial results reported
- • No cash flow, capital allocation, buybacks, dividends, or capex information included
- • Forward-looking statements mentioned with general risk disclosure but no specific guidance or outlook
Risk Factors
- • Regulatory risk: FDA breakthrough designation for DT120 in GAD requires successful Phase 3 trials (Voyage, Panorama) with topline readouts in 2026
- • Geopolitical/macro risk: Clinical trial enrollment and drug supply dependent on U.S. regulations and foreign currency exchange fluctuations affecting expenses
- • Operational risk: Dependence on contract research and manufacturing organizations for clinical trials and cGMP-compliant product supply
- • Competitive risk: Psychedelic drug market includes competitors developing alternative therapies for brain health disorders (no named competitor disclosed)
- • Financial risk: $411.6M cash as of Dec 31, 2025, expected funding into 2028, but reliance on future equity/debt raises could dilute shareholders or impose restrictive covenants
Definium Therapeutics, Inc. FY2025 Key Financial MetricsXBRL
Net Income
-$184M
▼ -69.1% YoY
ROE
-55.3%
▼ -1029bp YoY
Total Assets
$440M
▲ +45.7% YoY
EPS (Diluted)
$-2.06
▼ -33.8% YoY
Operating Cash Flow
-$132M
▼ -66.3% YoY
Source: XBRL data from Definium Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Definium Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.